v3.25.2
STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
Common Stock
Additional Paid-in Capital
Retained Deficit
Total
Balance at Feb. 29, 2024 $ 131,449 $ 127,933,634 $ (128,090,206) $ (25,123)
Balance (in shares) at Feb. 29, 2024 131,448,444      
Increase (Decrease) in Stockholders' Equity        
Cash contributed by S.R. Burzynski M.D., Ph.D.   58,517   58,517
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.   210,070   210,070
Net loss     (371,332) (371,332)
Balance at May. 31, 2024 $ 131,449 128,202,221 (128,461,538) (127,868)
Balance (in shares) at May. 31, 2024 131,448,444      
Balance at Feb. 28, 2025 $ 131,449 129,303,327 (129,476,413) (41,637)
Balance (in shares) at Feb. 28, 2025 131,448,444      
Increase (Decrease) in Stockholders' Equity        
Cash contributed by S.R. Burzynski M.D., Ph.D.   49,117   49,117
FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.   254,255   254,255
Net loss     (331,451) (331,451)
Balance at May. 31, 2025 $ 131,449 $ 129,606,699 $ (129,807,864) $ (69,716)
Balance (in shares) at May. 31, 2025 131,448,444